Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 20/20 | 0.60 |
| ▸ | TNF | P01375 | 4/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22695168 | 0.89 | IL1B (0.47) | IL1BTNFNLRP3 | |
| SCHEMBL22654856 | 0.82 | IL1B (0.58) | IL1BTNFNLRP3 | |
| SCHEMBL31404964 | 0.82 | IL1B (0.60) | IL1BTNFNLRP3 | |
| Hydrochloric Acid SCHEMBL31404990 | 0.81 | IL1B (0.59) | IL1BTNFNLRP3 | |
| SCHEMBL22695042 | 0.81 | IL1B (0.57) | IL1BTNFNLRP3 | |
| SCHEMBL31233716 | 0.79 | IL1B (0.51) | IL1BTNFNLRP3 | |
| SCHEMBL31404960 | 0.79 | IL1B (0.58) | IL1BTNFNLRP3 | |
| SCHEMBL31404971 | 0.79 | IL1B (0.58) | IL1BTNFNLRP3 | |
| SCHEMBL22695045 | 0.78 | IL1B (0.61) | IL1BTNFNLRP3 | |
| SCHEMBL24695709 | 0.78 | IL1B (0.51) | IL1BTNFNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.